{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:06:14Z","timestamp":1770959174083,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fertil Res and Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A number of studies have looked at dual triggers with hCG and GnRH agonist (GnRHa) in varying doses, but the question remains: what is the optimal dose of hCG to minimize ovarian hyperstimulation syndrome (OHSS) and still offer adequate pregnancy rates? The purpose of this study was to compare pregnancy and OHSS rates following dual trigger for oocyte maturation with GnRHa and a low-dose hCG versus hCG alone. A secondary objective was the assess pregnancy outcomes in subsequent frozen cycles for the same population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 963 women &lt;\u200941\u2009years old, with a BMI 18\u201340\u2009kg\/m<jats:sup>2<\/jats:sup> and an AMH\u2009&gt;\u20092\u2009ng\/mL who underwent fresh autologous in vitro fertilization (IVF) with GnRH antagonist protocol at a University-based fertility center were included in this retrospective cohort study. Those who received a low dose dual trigger with hCG (1000u) and GnRHa (2\u2009mg) were compared to those who received hCG alone (10,000u hCG\/250-500\u2009\u03bcg Ovidrel). Differences in implantation rates, pregnancy, live birth, and OHSS were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The dual trigger group was younger (mean 33.6 vs 34.1\u2009years), had a higher AMH (6.3 vs 4.9\u2009ng\/mL,) more oocytes retrieved (18.1 vs 14.9) and a higher fertilized oocyte rate (80% vs 77%) compared with the hCG only group. Yet, the dual trigger group had a lower probability of clinical pregnancy (gestational sac, 43.4% vs 52.8%) and live birth (33.4% vs 45.8%), all of which were statistically significant. There were 3 cases of OHSS, all in the hCG-only trigger group. In subsequent frozen cycles, pregnancy rates were comparable between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The dual trigger group had a better prognosis based on age and AMH levels and had better stimulation outcomes, but significantly worse pregnancy outcomes, suggesting the low dose hCG (1000u) in the dual trigger may not have provided adequate luteal support, compared to an hCG-only trigger (10,000u hCG\/250-500\u2009\u03bcg Ovidrel). Interestingly, the pregnancy rates were comparable in subsequent frozen cycles, further supporting the hypothesis that the issue lies in inadequate luteal phase support, rather than embryo quality. Based on these findings, our program has changed the protocol to 1500u of hCG in a dual trigger.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40738-021-00104-8","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:05:20Z","timestamp":1622174720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low dose hCG supplementation in a Gn-RH-agonist trigger protocol is associated with worse pregnancy outcomes: a retrospective cohort study"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-7773","authenticated-orcid":false,"given":"Maren","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Romanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Yanushpolsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"104_CR1","first-page":"733.e8","volume-title":"Yen & jaffe\u2019s reproductive endocrinology","author":"NS Macklon","year":"2014","unstructured":"Macklon NS, Fauser BC. Chapter 30 - medical approaches to ovarian stimulation for infertility. In: Strauss JF, Barbieri RL, editors. Yen & jaffe\u2019s reproductive endocrinology. seventh ed. Philadelphia: W.B. Saunders; 2014. p. 733.e8. http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9781455727582000305. \/\/doi.org\/10.1016\/B978-1-4557-2758-2.00030-5.","edition":"seventh"},{"issue":"6","key":"104_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559\u201377 Accessed Jun 14, 2017.","journal-title":"Hum Reprod Update."},{"issue":"7","key":"104_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/humrep\/deq080","volume":"25","author":"DDM Braat","year":"2010","unstructured":"Braat DDM, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in the netherlands 1984\u20132008. Hum Reprod. 2010;25(7):1782\u20136. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1093\/humrep\/deq080.","journal-title":"Hum Reprod."},{"issue":"6","key":"104_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/humrep\/12.6.1129","volume":"12","author":"U Elchalal","year":"1997","unstructured":"Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod. 1997;12(6):1129\u201337 Accessed Jun 14, 2017.","journal-title":"Hum Reprod."},{"issue":"10","key":"104_CR5","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/humrep\/der251","volume":"26","author":"P Devroey","year":"2011","unstructured":"Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593\u20137. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1093\/humrep\/der251.","journal-title":"Hum Reprod."},{"key":"104_CR6","unstructured":"Devroey P, Adriaensen P. OHSS free clinic. Facts, views & vision in ObGyn. 2011;3(1):43. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24753847."},{"issue":"10","key":"104_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10815-016-0775-4","volume":"33","author":"R Orvieto","year":"2016","unstructured":"Orvieto R. Triggering final follicular maturation\u2014hCG, GnRH-agonist or both, when and to whom? J Assist Reprod Genet. 2016;33(10):1415\u20136. http:\/\/search.proquest.com\/docview\/1828863078. https:\/\/doi.org\/10.1007\/s10815-016-0775-4.","journal-title":"J Assist Reprod Genet."},{"issue":"2","key":"104_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/09513590.2014.978850","volume":"31","author":"E Zilberberg","year":"2015","unstructured":"Zilberberg E, Haas J, Dar S, Kedem A, Machtinger R, Orvieto R. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Gynecol Endocrinol. 2015;31(2):145\u20137. Accessed Jun 14, 2017. https:\/\/doi.org\/10.3109\/09513590.2014.978850.","journal-title":"Gynecol Endocrinol."},{"key":"104_CR9","doi-asserted-by":"publisher","unstructured":"Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;(10):CD008046. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1002\/14651858.CD008046.pub4.","DOI":"10.1002\/14651858.CD008046.pub4"},{"key":"104_CR10","doi-asserted-by":"publisher","first-page":"CD001750","DOI":"10.1002\/14651858.CD001750.pub4","volume":"4","author":"HG Al-Inany","year":"2016","unstructured":"Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1002\/14651858.CD001750.pub4.","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"104_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/humrep\/15.9.1965","volume":"15","author":"J Itskovitz-Eldor","year":"2000","unstructured":"Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Preliminary report: Short communication. Hum Reprod. 2000;15(9):1965\u20138 Accessed Jun 14, 2017.","journal-title":"Hum Reprod."},{"key":"104_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/humupd\/dmr008","volume":"17","author":"P Humaidan","year":"2011","unstructured":"Humaidan P, Kol S, Papanikolaou EG, Copenhagen GnRH Agonist Trig- gering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17:510\u201324.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"104_CR13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S0015-0282(16)53524-9","volume":"53","author":"RJ Paulson","year":"1990","unstructured":"Paulson RJ, Sauer MV, Lobo RA. Embryo implantation after human in vitro fertilization: Importance of endometrial receptivity. Fertil Steril. 1990;53(5):870\u20134 Accessed Jun 14, 2017.","journal-title":"Fertil Steril."},{"key":"104_CR14","doi-asserted-by":"publisher","first-page":"CD009154","DOI":"10.1002\/14651858.CD009154.pub3","volume":"7","author":"M van der Linden","year":"2015","unstructured":"van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1002\/14651858.CD009154.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"104_CR15","doi-asserted-by":"publisher","first-page":"946.e3","DOI":"10.1016\/j.fertnstert.2014.12.125","volume":"103","author":"MT Connell","year":"2015","unstructured":"Connell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril. 2015;103(4):946.e3. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.12.125.","journal-title":"Fertil Steril"},{"key":"104_CR16","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1093\/humrep\/det249","volume":"28","author":"P Humaidan","year":"2013","unstructured":"Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013;28:2511\u201321.","journal-title":"Hum Reprod."},{"issue":"5","key":"104_CR17","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.fertnstert.2013.07.1976","volume":"100","author":"M Lin","year":"2013","unstructured":"Lin M, Wu FS, Lee RK, Li S, Lin S, Hwu Y. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013;100(5):1296\u2013302. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.07.1976.","journal-title":"Fertil Steril."},{"issue":"9","key":"104_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jog.13021","volume":"42","author":"MM Seval","year":"2016","unstructured":"Seval MM, \u00d6zmen B, Atabeko\u011flu C, et al. Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. J Obstet Gynaecol Res. 2016;42(9):1146\u201351. http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jog.13021\/abstract. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1111\/jog.13021.","journal-title":"J Obstet Gynaecol Res."},{"issue":"6","key":"104_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10815-017-0917-3","volume":"34","author":"RT Elias","year":"2017","unstructured":"Elias RT, Pereira N, Artusa L, et al. Combined GnRH-agonist and human chorionic gonadotropin trigger improves ICSI cycle outcomes in patients with history of poor fertilization. J Assist Reprod Genet. 2017;34(6):781\u20138. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1007\/s10815-017-0917-3.","journal-title":"J Assist Reprod Genet."},{"issue":"2","key":"104_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/0974-1208.183506","volume":"9","author":"N Mahajan","year":"2016","unstructured":"Mahajan N, Sharma S, Arora PR, Gupta S, Rani K, Naidu P. Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: a prospective randomized study. J Hum Reprod Sci. 2016;9(2):101\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4915279\/. Accessed Jun 14, 2017. https:\/\/doi.org\/10.4103\/0974-1208.183506.","journal-title":"J Hum Reprod Sci"},{"issue":"4","key":"104_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5935\/1518-0557.20160047","volume":"20","author":"Oliveira SAd, Calsavara VF, Cort\u00e9s","year":"2016","unstructured":"Oliveira SAd, Calsavara VF, Cort\u00e9s GC. Final oocyte maturation in assisted reproduction with human chorionic gonadotropin and gonadotropin-releasing hormone agonist (dual trigger). JBRA Assist Reprod. 2016;20(4):246\u201350. Accessed Jun 14, 2017. https:\/\/doi.org\/10.5935\/1518-0557.20160047.","journal-title":"JBRA Assist Reprod"},{"issue":"8","key":"104_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.fertnstert.2011.03.109","volume":"95","author":"BS Shapiro","year":"2011","unstructured":"Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Comparison of \u201ctriggers\u201d using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011;95(8):2715\u20137.","journal-title":"Fertil Steril"},{"issue":"6","key":"104_CR23","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.fertnstert.2012.03.015","volume":"97","author":"D Griffin","year":"2012","unstructured":"Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril. 2012;97(6):1316\u201320. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.03.015.","journal-title":"Fertil Steril."},{"issue":"2","key":"104_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.fertnstert.2014.04.028","volume":"102","author":"D Griffin","year":"2014","unstructured":"Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertil Steril. 2014;102(2):405\u20139. Accessed Jun 14, 2017. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.04.028.","journal-title":"Fertil Steril."},{"issue":"9","key":"104_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s10815-016-0755-8","volume":"33","author":"K O\u2019Neill","year":"2016","unstructured":"O\u2019Neill K, Senapati S, Maina I, Gracia C, Dokras A. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet. 2016;33(9):1175\u201384. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27349252. https:\/\/doi.org\/10.1007\/s10815-016-0755-8.","journal-title":"J Assist Reprod Genet."},{"key":"104_CR26","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s10815-019-01580-0","volume":"36","author":"JB Bakkensen","year":"2019","unstructured":"Bakkensen JB, Brady P, Carusi D, Romanski P, Thomas AM, Racowsky C. Association between blastocyst morphology and pregnancy and perinatal outcomes following fresh and cryopreserved embryo transfer. J Assist Reprod Genet. 2019;36:2315\u201324.","journal-title":"J Assist Reprod Genet."},{"key":"104_CR27","doi-asserted-by":"publisher","first-page":"163.e1","DOI":"10.1016\/j.ajog.2014.03.035","volume":"211","author":"AP Bailey","year":"2014","unstructured":"Bailey AP, Hawkins LK, Missmer SA, Correia KF, Yanushpolsky EH. Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. Am J Obstet Gynecol. 2014;211:163.e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"104_CR28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106:1634\u201347.","journal-title":"Fertil Steril"},{"issue":"7","key":"104_CR29","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.fertnstert.2010.02.033","volume":"94","author":"E Yanushpolsky","year":"2010","unstructured":"Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010;94(7):2596\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.02.033.","journal-title":"Fertil Steril."},{"issue":"2","key":"104_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.fertnstert.2007.03.006","volume":"89","author":"E Yanushpolsky","year":"2008","unstructured":"Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization\/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89(2):485\u20137. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.03.006.","journal-title":"Fertil Steril."},{"issue":"2","key":"104_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.fertnstert.2009.10.004","volume":"94","author":"S Kahraman","year":"2010","unstructured":"Kahraman S, Karagozoglu SH, Karlikaya G. The efficiency of progesterone vaginal gel versus intramuscular progesterone for luteal phase supplementation in gonadotropin-releasing hormone antagonist cycles: a prospective clinical trial. Fertil Steril. 2010;94(2):761\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.10.004.","journal-title":"Fertil Steril."},{"issue":"7","key":"104_CR32","doi-asserted-by":"publisher","first-page":"CD009154","DOI":"10.1002\/14651858.CD009154.pub3","volume":"2015","author":"M van der Linden","year":"2015","unstructured":"van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;2015(7):CD009154. Published 2015 Jul 7. https:\/\/doi.org\/10.1002\/14651858.CD009154.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"104_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.fertnstert.2007.11.049","volume":"91","author":"D Bodri","year":"2009","unstructured":"Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist\u2013treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365\u201371.","journal-title":"Fertil Steril."},{"key":"104_CR34","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/humrep\/deh765","volume":"20","author":"P Humaidan","year":"2005","unstructured":"Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF\/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213\u201320.","journal-title":"Hum Reprod."},{"key":"104_CR35","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1093\/humrep\/dei150","volume":"20","author":"EM Kolibianakis","year":"2005","unstructured":"Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887\u201392.","journal-title":"Hum Reprod."},{"key":"104_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/humupd\/dmi045","volume":"12","author":"G Griesinger","year":"2006","unstructured":"Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159\u201368.","journal-title":"Hum Reprod Update"},{"key":"104_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.rbmo.2016.08.009","volume":"33","author":"N Pereira","year":"2016","unstructured":"Pereira N, Elias RT, Neri QV, Gerber RS, Lekovich JP, Palermo GD, et al. Adjuvant gonadotrophin-releasing hormone agonist trigger with human chorionic gonadotrophin to enhance ooplasmic maturity. Reprod Biomed Online. 2016;33:568\u201374.","journal-title":"Reprod Biomed Online."}],"container-title":["Fertility Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40738-021-00104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40738-021-00104-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40738-021-00104-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:05:42Z","timestamp":1622174742000},"score":1,"resource":{"primary":{"URL":"https:\/\/fertilityresearchandpractice.biomedcentral.com\/articles\/10.1186\/s40738-021-00104-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1186\/s40738-021-00104-8","relation":{},"ISSN":["2054-7099"],"issn-type":[{"value":"2054-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. The need for consent was waived. The Partners Health System IRB approved this study (Protocol 2017P001579).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}